Biopharma Investor's Letter Dooms Officer Salary Suit
A Delaware vice chancellor on Wednesday tossed an investor suit against biopharmaceutical company Ultragenyx Pharmaceutical Inc. over alleged excessive board salaries, ruling the stockholder's derivative action was procedurally flawed because he...To view the full article, register now.
Already a subscriber? Click here to view full article